Large animal and primate models of spinal cord injury for the testing of novel therapies

Brian K. Kwon, Femke Streijger, Caitlin E. Hill, Aileen J. Anderson, Mark Bacon, Michael S. Beattie, Armin Blesch, Elizabeth J. Bradbury, Arthur Brown, Jacqueline C. Bresnahan, Casey C. Case, Raymond W. Colburn, Samuel David, James W. Fawcett, Adam R. Ferguson, Itzhak Fischer, Candace L. Floyd, John C. Gensel, John D. Houle, Lyn B. JakemanNick D. Jeffery, Linda Ann Truett Jones, Naomi Kleitman, Jeffery Kocsis, Paul Lu, David S K Magnuson, Martin Marsala, Simon W. Moore, Andrea J. Mothe, Martin Oudega, Giles W. Plant, Alexander Sasha Rabchevsky, Jan M. Schwab, Jerry Silver, Oswald Steward, Xiao-Ming Xu, James D. Guest, Wolfram Tetzlaff

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Large animal and primate models of spinal cord injury (SCI) are being increasingly utilized for the testing of novel therapies. While these represent intermediary animal species between rodents and humans and offer the opportunity to pose unique research questions prior to clinical trials, the role that such large animal and primate models should play in the translational pipeline is unclear. In this initiative we engaged members of the SCI research community in a questionnaire and round-table focus group discussion around the use of such models. Forty-one SCI researchers from academia, industry, and granting agencies were asked to complete a questionnaire about their opinion regarding the use of large animal and primate models in the context of testing novel therapeutics. The questions centered around how large animal and primate models of SCI would be best utilized in the spectrum of preclinical testing, and how much testing in rodent models was warranted before employing these models. Further questions were posed at a focus group meeting attended by the respondents. The group generally felt that large animal and primate models of SCI serve a potentially useful role in the translational pipeline for novel therapies, and that the rational use of these models would depend on the type of therapy and specific research question being addressed. While testing within these models should not be mandatory, the detection of beneficial effects using these models lends additional support for translating a therapy to humans. These models provides an opportunity to evaluate and refine surgical procedures prior to use in humans, and safety and bio-distribution in a spinal cord more similar in size and anatomy to that of humans. Our results reveal that while many feel that these models are valuable in the testing of novel therapies, important questions remain unanswered about how they should be used and how data derived from them should be interpreted.

Original languageEnglish
Pages (from-to)154-168
Number of pages15
JournalExperimental Neurology
Volume269
DOIs
StatePublished - Jul 1 2015

Fingerprint

Spinal Cord Injuries
Primates
Animal Models
Focus Groups
Rodentia
Therapeutics
Research
Group Processes
Spinal Cord
Anatomy
Industry
Research Personnel
Clinical Trials
Safety
Surveys and Questionnaires

Keywords

  • Cellular therapies
  • Drug therapies
  • Large animal models
  • Primate models
  • Questionnaire
  • Translation

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience
  • Medicine(all)

Cite this

Kwon, B. K., Streijger, F., Hill, C. E., Anderson, A. J., Bacon, M., Beattie, M. S., ... Tetzlaff, W. (2015). Large animal and primate models of spinal cord injury for the testing of novel therapies. Experimental Neurology, 269, 154-168. https://doi.org/10.1016/j.expneurol.2015.04.008

Large animal and primate models of spinal cord injury for the testing of novel therapies. / Kwon, Brian K.; Streijger, Femke; Hill, Caitlin E.; Anderson, Aileen J.; Bacon, Mark; Beattie, Michael S.; Blesch, Armin; Bradbury, Elizabeth J.; Brown, Arthur; Bresnahan, Jacqueline C.; Case, Casey C.; Colburn, Raymond W.; David, Samuel; Fawcett, James W.; Ferguson, Adam R.; Fischer, Itzhak; Floyd, Candace L.; Gensel, John C.; Houle, John D.; Jakeman, Lyn B.; Jeffery, Nick D.; Jones, Linda Ann Truett; Kleitman, Naomi; Kocsis, Jeffery; Lu, Paul; Magnuson, David S K; Marsala, Martin; Moore, Simon W.; Mothe, Andrea J.; Oudega, Martin; Plant, Giles W.; Rabchevsky, Alexander Sasha; Schwab, Jan M.; Silver, Jerry; Steward, Oswald; Xu, Xiao-Ming; Guest, James D.; Tetzlaff, Wolfram.

In: Experimental Neurology, Vol. 269, 01.07.2015, p. 154-168.

Research output: Contribution to journalArticle

Kwon, BK, Streijger, F, Hill, CE, Anderson, AJ, Bacon, M, Beattie, MS, Blesch, A, Bradbury, EJ, Brown, A, Bresnahan, JC, Case, CC, Colburn, RW, David, S, Fawcett, JW, Ferguson, AR, Fischer, I, Floyd, CL, Gensel, JC, Houle, JD, Jakeman, LB, Jeffery, ND, Jones, LAT, Kleitman, N, Kocsis, J, Lu, P, Magnuson, DSK, Marsala, M, Moore, SW, Mothe, AJ, Oudega, M, Plant, GW, Rabchevsky, AS, Schwab, JM, Silver, J, Steward, O, Xu, X-M, Guest, JD & Tetzlaff, W 2015, 'Large animal and primate models of spinal cord injury for the testing of novel therapies', Experimental Neurology, vol. 269, pp. 154-168. https://doi.org/10.1016/j.expneurol.2015.04.008
Kwon, Brian K. ; Streijger, Femke ; Hill, Caitlin E. ; Anderson, Aileen J. ; Bacon, Mark ; Beattie, Michael S. ; Blesch, Armin ; Bradbury, Elizabeth J. ; Brown, Arthur ; Bresnahan, Jacqueline C. ; Case, Casey C. ; Colburn, Raymond W. ; David, Samuel ; Fawcett, James W. ; Ferguson, Adam R. ; Fischer, Itzhak ; Floyd, Candace L. ; Gensel, John C. ; Houle, John D. ; Jakeman, Lyn B. ; Jeffery, Nick D. ; Jones, Linda Ann Truett ; Kleitman, Naomi ; Kocsis, Jeffery ; Lu, Paul ; Magnuson, David S K ; Marsala, Martin ; Moore, Simon W. ; Mothe, Andrea J. ; Oudega, Martin ; Plant, Giles W. ; Rabchevsky, Alexander Sasha ; Schwab, Jan M. ; Silver, Jerry ; Steward, Oswald ; Xu, Xiao-Ming ; Guest, James D. ; Tetzlaff, Wolfram. / Large animal and primate models of spinal cord injury for the testing of novel therapies. In: Experimental Neurology. 2015 ; Vol. 269. pp. 154-168.
@article{77a9a27005144c82999849cc86ab584d,
title = "Large animal and primate models of spinal cord injury for the testing of novel therapies",
abstract = "Large animal and primate models of spinal cord injury (SCI) are being increasingly utilized for the testing of novel therapies. While these represent intermediary animal species between rodents and humans and offer the opportunity to pose unique research questions prior to clinical trials, the role that such large animal and primate models should play in the translational pipeline is unclear. In this initiative we engaged members of the SCI research community in a questionnaire and round-table focus group discussion around the use of such models. Forty-one SCI researchers from academia, industry, and granting agencies were asked to complete a questionnaire about their opinion regarding the use of large animal and primate models in the context of testing novel therapeutics. The questions centered around how large animal and primate models of SCI would be best utilized in the spectrum of preclinical testing, and how much testing in rodent models was warranted before employing these models. Further questions were posed at a focus group meeting attended by the respondents. The group generally felt that large animal and primate models of SCI serve a potentially useful role in the translational pipeline for novel therapies, and that the rational use of these models would depend on the type of therapy and specific research question being addressed. While testing within these models should not be mandatory, the detection of beneficial effects using these models lends additional support for translating a therapy to humans. These models provides an opportunity to evaluate and refine surgical procedures prior to use in humans, and safety and bio-distribution in a spinal cord more similar in size and anatomy to that of humans. Our results reveal that while many feel that these models are valuable in the testing of novel therapies, important questions remain unanswered about how they should be used and how data derived from them should be interpreted.",
keywords = "Cellular therapies, Drug therapies, Large animal models, Primate models, Questionnaire, Translation",
author = "Kwon, {Brian K.} and Femke Streijger and Hill, {Caitlin E.} and Anderson, {Aileen J.} and Mark Bacon and Beattie, {Michael S.} and Armin Blesch and Bradbury, {Elizabeth J.} and Arthur Brown and Bresnahan, {Jacqueline C.} and Case, {Casey C.} and Colburn, {Raymond W.} and Samuel David and Fawcett, {James W.} and Ferguson, {Adam R.} and Itzhak Fischer and Floyd, {Candace L.} and Gensel, {John C.} and Houle, {John D.} and Jakeman, {Lyn B.} and Jeffery, {Nick D.} and Jones, {Linda Ann Truett} and Naomi Kleitman and Jeffery Kocsis and Paul Lu and Magnuson, {David S K} and Martin Marsala and Moore, {Simon W.} and Mothe, {Andrea J.} and Martin Oudega and Plant, {Giles W.} and Rabchevsky, {Alexander Sasha} and Schwab, {Jan M.} and Jerry Silver and Oswald Steward and Xiao-Ming Xu and Guest, {James D.} and Wolfram Tetzlaff",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.expneurol.2015.04.008",
language = "English",
volume = "269",
pages = "154--168",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Large animal and primate models of spinal cord injury for the testing of novel therapies

AU - Kwon, Brian K.

AU - Streijger, Femke

AU - Hill, Caitlin E.

AU - Anderson, Aileen J.

AU - Bacon, Mark

AU - Beattie, Michael S.

AU - Blesch, Armin

AU - Bradbury, Elizabeth J.

AU - Brown, Arthur

AU - Bresnahan, Jacqueline C.

AU - Case, Casey C.

AU - Colburn, Raymond W.

AU - David, Samuel

AU - Fawcett, James W.

AU - Ferguson, Adam R.

AU - Fischer, Itzhak

AU - Floyd, Candace L.

AU - Gensel, John C.

AU - Houle, John D.

AU - Jakeman, Lyn B.

AU - Jeffery, Nick D.

AU - Jones, Linda Ann Truett

AU - Kleitman, Naomi

AU - Kocsis, Jeffery

AU - Lu, Paul

AU - Magnuson, David S K

AU - Marsala, Martin

AU - Moore, Simon W.

AU - Mothe, Andrea J.

AU - Oudega, Martin

AU - Plant, Giles W.

AU - Rabchevsky, Alexander Sasha

AU - Schwab, Jan M.

AU - Silver, Jerry

AU - Steward, Oswald

AU - Xu, Xiao-Ming

AU - Guest, James D.

AU - Tetzlaff, Wolfram

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Large animal and primate models of spinal cord injury (SCI) are being increasingly utilized for the testing of novel therapies. While these represent intermediary animal species between rodents and humans and offer the opportunity to pose unique research questions prior to clinical trials, the role that such large animal and primate models should play in the translational pipeline is unclear. In this initiative we engaged members of the SCI research community in a questionnaire and round-table focus group discussion around the use of such models. Forty-one SCI researchers from academia, industry, and granting agencies were asked to complete a questionnaire about their opinion regarding the use of large animal and primate models in the context of testing novel therapeutics. The questions centered around how large animal and primate models of SCI would be best utilized in the spectrum of preclinical testing, and how much testing in rodent models was warranted before employing these models. Further questions were posed at a focus group meeting attended by the respondents. The group generally felt that large animal and primate models of SCI serve a potentially useful role in the translational pipeline for novel therapies, and that the rational use of these models would depend on the type of therapy and specific research question being addressed. While testing within these models should not be mandatory, the detection of beneficial effects using these models lends additional support for translating a therapy to humans. These models provides an opportunity to evaluate and refine surgical procedures prior to use in humans, and safety and bio-distribution in a spinal cord more similar in size and anatomy to that of humans. Our results reveal that while many feel that these models are valuable in the testing of novel therapies, important questions remain unanswered about how they should be used and how data derived from them should be interpreted.

AB - Large animal and primate models of spinal cord injury (SCI) are being increasingly utilized for the testing of novel therapies. While these represent intermediary animal species between rodents and humans and offer the opportunity to pose unique research questions prior to clinical trials, the role that such large animal and primate models should play in the translational pipeline is unclear. In this initiative we engaged members of the SCI research community in a questionnaire and round-table focus group discussion around the use of such models. Forty-one SCI researchers from academia, industry, and granting agencies were asked to complete a questionnaire about their opinion regarding the use of large animal and primate models in the context of testing novel therapeutics. The questions centered around how large animal and primate models of SCI would be best utilized in the spectrum of preclinical testing, and how much testing in rodent models was warranted before employing these models. Further questions were posed at a focus group meeting attended by the respondents. The group generally felt that large animal and primate models of SCI serve a potentially useful role in the translational pipeline for novel therapies, and that the rational use of these models would depend on the type of therapy and specific research question being addressed. While testing within these models should not be mandatory, the detection of beneficial effects using these models lends additional support for translating a therapy to humans. These models provides an opportunity to evaluate and refine surgical procedures prior to use in humans, and safety and bio-distribution in a spinal cord more similar in size and anatomy to that of humans. Our results reveal that while many feel that these models are valuable in the testing of novel therapies, important questions remain unanswered about how they should be used and how data derived from them should be interpreted.

KW - Cellular therapies

KW - Drug therapies

KW - Large animal models

KW - Primate models

KW - Questionnaire

KW - Translation

UR - http://www.scopus.com/inward/record.url?scp=84928579017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928579017&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2015.04.008

DO - 10.1016/j.expneurol.2015.04.008

M3 - Article

C2 - 25902036

AN - SCOPUS:84928579017

VL - 269

SP - 154

EP - 168

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

ER -